Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Obesity or Overweight With Comorbidity

NCT06595238 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06595238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06595238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Obesity or Overweight With Comorbidity
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2024
Completion date
December 3, 2025
Enrollment
262 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

obesity or overweight